1 | 08:45-08:55 | 引导报告 |
美国妇科肿瘤专科医师培训制度介绍 |
|
||||||||||||||||
2 | 08:55-09:05 | 引导报告 |
韩国妇科肿瘤专科医师培训制度介绍 |
|
||||||||||||||||
3 | 09:05-09:15 | 引导报告 |
中国台湾妇科肿瘤专科医师培训介绍 |
|
||||||||||||||||
4 | 09:15-09:25 | 引导报告 |
中国香港妇科肿瘤专科医师培训介绍 |
|
||||||||||||||||
5 | 09:25-09:35 | 引导报告 |
中国抗癌协会妇瘤专科医师培训介绍 |
|
||||||||||||||||
6 | 09:35-10:30 |
讨论 |
|
1 | 11:00-11:05 | 论文发言 |
Artificial Intelligence for Predictive Biomarker in Gynecological Oncology: A Scoping Review of Technical Challenges and Clinical Translation |
|
||||
2 | 11:05-11:10 | 论文发言 |
148例中国子宫肉瘤患者临床病理特征及预后分析 |
|
||||
3 | 11:10-11:15 | 论文发言 |
The Role of Central Nervous System Tumor Methylation Classifier in the Classification of Ovarian Primitive Neuroectodermal Tumor |
|
||||
4 | 11:15-11:20 | 论文发言 |
Management and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: a long-term retrospective study |
|
||||
5 | 11:20-11:25 | 论文发言 |
基于免疫特征的妇科透明细胞癌分子分型及临床意义 |
|
||||
6 | 11:25-11:30 | 论文发言 |
女性生殖系统肝样腺癌临床病理特征及全基因组测序分析 |
|
||||
7 | 11:30-11:35 | 论文发言 |
妇科恶性肿瘤术后淋巴囊肿并发感染的高危因素分析 |
|
||||
8 | 11:35-11:40 | 论文发言 |
卵巢恶性生殖细胞肿瘤循环肿瘤DNA的检测及应用 |
|
||||
9 | 11:40-11:45 | 论文发言 |
妇科恶性肿瘤患者术后肺栓塞的临床特征分析与临床防治策略 |
|
||||
10 | 11:45-11:50 | 论文发言 |
耐药妊娠滋养细胞肿瘤患者的预后危险因素 |
|
||||
11 | 11:50-12:00 |
讨论交流 |
1 | 13:00-13:30 | 专题会发言 |
卵巢癌相关血小板减少症全病程管理 |
|
1 | 13:30-13:50 | 引导报告 |
International Collaborative Clinical Trials |
|
||||||||
2 | 13:50-14:10 | 引导报告 |
临床研究设计中创新思维 |
|
||||||||
3 | 14:10-14:17 | 引导报告 |
临床研究实施过程中的问题与处理 |
|
||||||||
4 | 14:17-14:24 | 引导报告 |
低危滋养细胞肿瘤的临床研究 |
|
||||||||
5 | 14:24-14:31 | 引导报告 |
复旦肿瘤临床试验经验分享 |
|
||||||||
6 | 14:31-14:38 | 引导报告 |
坚守与放弃——IIT研究的思考 |
|
||||||||
7 | 14:38-14:45 | 引导报告 |
临床研究思与行 |
|
||||||||
8 | 14:45-14:52 | 引导报告 |
如何胜任临床研究者的角色 |
|
||||||||
9 | 14:52-15:30 |
讨论 |
|
1 | 16:00-16:07 | 引导报告 |
妇科肿瘤MDT实施的重要性 |
|
||||||||||||||
2 | 16:07-16:14 | 引导报告 |
妇科肿瘤术中联合脏器切除的考量与实施 |
|
||||||||||||||
3 | 16:14-16:21 | 引导报告 |
MDT在妇科肿瘤术后综合治疗中的作用与价值 |
|
||||||||||||||
4 | 16:21-17:00 |
讨论 |
|
1 | 17:00-17:05 | 论文发言 |
多学科诊疗模式在卵巢癌肝及肝周转移手术中的实践分析 |
|
||||
2 | 17:05-17:10 | 论文发言 |
Web of Science 核心合集2005—2025年间妇科恶性肿瘤生育力保存研究的文献计量与可视化分析 |
|
||||
3 | 17:10-17:15 | 论文发言 |
Epitranscriptomic mechanisms and implications of RNA m5C modification in gynecologic cancer |
|
||||
4 | 17:15-17:20 | 论文发言 |
HPV Integration Initiates a Carcinogenic Positive Feedback Loop via Recognition of Stripe Transcription Factors |
|
||||
5 | 17:20-17:25 | 论文发言 |
STR分子分型技术辅助妊娠滋养细胞肿瘤成因诊断的应用 |
|
||||
6 | 17:25-17:30 | 论文发言 |
Precise treatment of chemotherapy-induced premature ovarian failure: A co-transplantation system for restoring dysfunctional ovaries |
|
||||
7 | 17:30-17:35 | 论文发言 |
Single-cell Landscape of the Tumor Immune Microenvironment in Human Gynecologic Malignancies |
|
||||
8 | 17:35-17:40 | 论文发言 |
负载纳米马达驱动型细胞外囊泡的水凝胶在治疗化疗诱导卵巢损伤中的应用研究 |
|
||||
9 | 17:40-17:45 | 论文发言 |
Evaluation of Individualized 3D Brachytherapy Strategies Based on HR-CTV Maximum Cross-Sectional Area: A Single-Center Retrospective Study |
|
||||
10 | 17:45-17:50 | 论文发言 |
基于不同分期探究外阴癌淋巴结转移相关因素分析 |
|
||||
11 | 17:50-18:00 |
讨论交流 |
1 | 08:45-09:20 | 议题 |
关于HPV检测:是否应该推广自采样?是否应该推广载量检测? |
|
||||||||||||
2 | 09:20-09:55 | 议题 |
中老年女性是否应该进行HPV疫苗接种? |
|
||||||||||||
3 | 09:55-10:30 | 议题 |
宫颈高级别病变锥切术前后是否应该接种HPV疫苗? |
|
1 | 11:00-11:05 | 论文发言 |
Exploring molecular heterogeneity and therapeutic targets of metastatic/recurrent cervical cancer based on deep analysis of large panel genes |
|
||||
2 | 11:05-11:10 | 论文发言 |
Genome-wide and Multi-omics Mapping of HPV Integration Signatures in Cervical Pre-Invasive and Invasive disease |
|
||||
3 | 11:10-11:15 | 论文发言 |
Preliminary Study on Prediction of Immune Microenvironment and Prognosis of Cervical Cancer Patients Based on MRI Radiomics before Treatment |
|
||||
4 | 11:15-11:20 | 论文发言 |
CS Ratio is an immune-related prognostic biomarker for cervical cancer |
|
||||
5 | 11:20-11:25 | 论文发言 |
宫颈癌中等分割在线自适应放疗的疗效及安全性分析:一项前瞻性单臂I期临床研究 |
|
||||
6 | 11:25-11:30 | 论文发言 |
CIN3外切缘阳性与进一步切子宫后的HPV延迟清除有关 |
|
||||
7 | 11:30-11:35 | 论文发言 |
ZBTB5 enhances the resistance of cervical cancer to paclitaxel by regulating BCL6 |
|
||||
8 | 11:35-11:40 | 论文发言 |
Effect of laparoscopic para-aortic and pelvic lymphadenectomy for patients with FIGO stage IIb-IIIC cervical cancer before CCRT:A single-center retrospective study |
|
||||
9 | 11:40-11:45 | 论文发言 |
宫颈癌前哨淋巴结不同转移对预后的影响:一项多中心真实世界回顾性研究 |
|
||||
10 | 11:50-12:00 |
讨论交流 |
1 | 13:00-13:30 | 专题会发言 |
双抗在宫颈癌的治疗进展和展望 |
|
1 | 13:30-13:38 | 引导报告 |
子宫颈癌手术的术式变迁 |
|
||||
2 | 13:38-13:46 | 引导报告 |
保留神经的广泛性子宫切除手术 |
|
||||
3 | 13:46-13:54 | 引导报告 |
子宫颈癌的微创手术相关问题 |
|
||||
4 | 13:54-14:02 | 引导报告 |
膜解剖下输尿管游离和宫颈旁组织切除 |
|
||||
5 | 14:02-14:10 | 引导报告 |
早期子宫颈癌前哨淋巴结活检相关问题 |
|
||||
6 | 14:10-14:18 | 引导报告 |
子宫颈癌手术中泌尿/直肠损伤问题 |
|
||||
7 | 14:18-15:30 |
讨论 |
1 | 15:30-16:00 | 专题会发言 |
从传统疗法到精准靶向——最适合复发或转移性宫颈癌的二线系统治疗方案 |
|
1 | 16:00-16:07 | 引导报告 |
外阴癌手术原则与辅助治疗 |
|
||||||||||||||
2 | 16:07-16:14 | 引导报告 |
阴道癌治疗原则与治疗困惑 |
|
||||||||||||||
3 | 16:14-16:21 | 引导报告 |
生殖道黑色素瘤的治疗 |
|
||||||||||||||
4 | 16:21-17:00 |
讨论 |
|
1 | 17:00-17:05 | 论文发言 |
Targeting Cervical Small Cell Neuroendocrine Carcinoma: A High-Throughput Drug Screening Approach Using Organoids |
|
||||
2 | 17:05-17:10 | 论文发言 |
TNFA在宫颈癌前病变演变中的作用及微生物驱动机制研究 |
|
||||
3 | 17:10-17:15 | 论文发言 |
68Ga-THP-NB1 PET/CT在晚期/复发性宫颈癌患者中PDL1表达的显像效果 |
|
||||
4 | 17:15-17:20 | 论文发言 |
HMGA2调控DNA损伤修复通路介导宫颈癌放疗抵抗的机制研究 |
|
||||
5 | 17:20-17:25 | 论文发言 |
替雷利珠单抗联合新辅助化疗治疗局部晚期宫颈癌的有效性及安全性研究 |
|
||||
6 | 17:25-17:30 | 论文发言 |
对巨块型宫颈癌发生宫旁浸润的影响因素及其治疗决策的探索 |
|
||||
7 | 17:30-17:35 | 论文发言 |
前哨淋巴结活检应用于早期宫颈癌的回顾性队列研究 |
|
||||
8 | 17:35-17:40 | 论文发言 |
ICCOR: Integrative Cervical Cancer Omics Resource |
|
||||
9 | 17:40-17:45 | 论文发言 |
Establishment of Patient-Derived Organoids for Gastric-Type Endocervical Adenocarcinoma |
|
||||
10 | 17:45-17:50 | 论文发言 |
Precision oncology guided by causal inference: Integrative multi-omics Mendelian randomization reveals immune-epigenetic crosstalk driving cervical carcinogenesis |
|
||||
11 | 17:50-18:00 |
讨论交流 |
1 | 19:00-19:10 | 视频展示 |
外阴癌皮瓣移植新思路 |
|
||||
2 | 19:10-19:20 | 视频展示 |
以最小创伤,谋最大获益——腹股沟淋巴结切除的腔镜解决方案 |
|
||||
3 | 19:20-19:30 | 视频展示 |
卵巢癌腹壁复发灶切除联合阔筋膜腹壁筋膜修补术一例 |
|
||||
4 | 19:30-19:40 | 视频展示 |
卵巢癌膈肌及心包肿瘤切除后膈肌修补术 |
|
||||
5 | 19:40-19:50 | 视频展示 |
全盆脏器切除手术视频 |
|
||||
6 | 19:50-20:00 | 视频展示 |
板状包绕型腹膜后淋巴结切除 |
|
1 | 20:00-20:10 | 视频展示 |
宫颈癌放疗后复发腹腔镜后盆腔脏器廓清术 |
|
||||
2 | 20:10-20:20 | 视频展示 |
复发性宫颈癌手术 |
|
||||
3 | 20:20-20:30 | 视频展示 |
破膈攻坚--膈肌病灶及心膈角淋巴结切除 |
|
||||
4 | 20:30-20:40 | 视频展示 |
静脉内平滑肌瘤手术分享 |
|
||||
5 | 20:40-20:50 | 视频展示 |
腹腔镜下宫旁广泛切除术 |
|
||||
6 | 20:50-21:00 | 视频展示 |
腹腔镜改良QM-C1型子宫切除术在早期宫颈癌中的优势 |
|
1 | 21:00-21:10 | 视频展示 |
隐匿性阴道直肠隔病灶切除 |
|
||||
2 | 21:10-21:20 | 视频展示 |
盆腔血管内平滑肌瘤R0切除术 |
|
||||
3 | 21:20-21:30 | 视频展示 |
磁牵引技术在妇科手术中的应用及发展前景 |
|
||||
4 | 21:30-21:40 | 视频展示 |
腹腔镜全阴道切除及前庭大腺肿物切除 |
|
||||
5 | 21:40-21:50 | 视频展示 |
卵巢癌超根治之肝门淋巴结切除术 |
|
||||
6 | 21:50-22:00 | 视频展示 |
机器人辅助腹腔镜下改良广泛子宫切除术 |
|
1 | 08:45-09:00 | 引导报告 |
在活检标本中如何正确认知HPV非相关性宫颈腺癌 |
|
||||||||||
2 | 09:00-09:20 |
讨论 |
|
|||||||||||
3 | 09:20-09:35 | 引导报告 |
雌激素受体阴性的子宫内膜癌 (ERneg-EC) |
|
||||||||||
4 | 09:35-09:55 |
讨论 |
|
|||||||||||
5 | 09:55-10:10 | 引导报告 |
卵巢癌高级别浆液性癌治疗相关分子标记检测 |
|
||||||||||
6 | 10:10-10:30 |
讨论 |
|
1 | 10:30-11:00 | 专题会发言 |
免疫检查点抑制剂再创新之路 |
|
1 | 11:00-11:05 | 论文发言 |
构建代谢评分系统预测子宫内膜癌临床结局并指导免疫治疗 |
|
||||
2 | 11:05-11:10 | 论文发言 |
Analysis of the Clinicopathological and Molecular Characteristics Associated with Risk of Lymph Node Metastasis in Endometrial Malignant Tumors |
|
||||
3 | 11:10-11:15 | 论文发言 |
西达本胺通过诱导核糖体翻译受损治疗子宫内膜癌的机制研究 |
|
||||
4 | 11:15-11:20 | 论文发言 |
Intratumor microbiome-derived butyrate facilitates progesterone resistance by inducing ferroptosis in endometrial cancer |
|
||||
5 | 11:20-11:25 | 论文发言 |
子宫内膜癌孕激素耐药的时序分子特征及逆转策略研究 |
|
||||
6 | 11:25-11:30 | 论文发言 |
肠道微生态与子宫内膜癌发生机制的相关性研究 |
|
||||
7 | 11:30-11:35 | 论文发言 |
Integration of Inflammatory and Nutritional Biomarkers with Machine Learning Enhances Prediction of Progesterone Response in Fertility-Preserving Endometrial Carcinoma Management |
|
||||
8 | 11:35-11:40 | 论文发言 |
NSMP亚型子宫内膜癌的临床病理特征及预后——一项单中心回顾性研究 |
|
||||
9 | 11:40-11:45 | 论文发言 |
基于多中心队列的早发性子宫内膜癌基因组及分子特征研究 |
|
||||
10 | 11:45-11:50 | 论文发言 |
子宫内膜癌诊断中宫腔镜应用与腹水细胞学阳性的相关性及风险因素分析 |
|
||||
11 | 11:50-12:00 |
讨论交流 |
1 | 13:00-13:30 | 专题会发言 |
免疫治疗在子宫内膜癌中的应用探索 |
|
1 | 13:30-13:38 | 引导报告 |
子宫内膜癌分子分型检测简化方案和NGS结合免疫组化方案的临床价值 |
|
||||
2 | 13:38-13:46 | 引导报告 |
多重分子特征子宫内膜癌的临床意义 |
|
||||
3 | 13:46-13:54 | 引导报告 |
侵袭性子宫内膜癌中分子分型的临床意义 |
|
||||
4 | 13:54-14:02 | 引导报告 |
分子分型对FIGO I-II期子宫内膜癌诊疗策略的影响 |
|
||||
5 | 14:02-14:10 | 引导报告 |
分子分型对晚期复发性子宫内膜癌诊疗策略的影响 |
|
||||
6 | 14:10-14:18 | 引导报告 |
分子分型对子宫内膜癌保留生育功能诊疗策略的影响 |
|
||||
7 | 14:18-15:30 |
讨论 |
1 | 15:30-16:00 | 专题会发言 |
晚期复发/转移EC二线治疗突破之旅 |
|
1 | 16:00-16:07 | 引导报告 |
FIGO 2023内膜癌分期的主要变化 |
|
||||||||||||||
2 | 16:07-16:14 | 引导报告 |
FIGO 2023中的IA3的诊断 |
|
||||||||||||||
3 | 16:14-16:21 | 引导报告 |
FIGO 2023分期临床应用面临的问题 |
|
||||||||||||||
4 | 16:21-17:00 |
讨论 |
|
1 | 17:00-17:05 | 论文发言 |
洛塞那肽联合左炔诺孕酮宫内缓释系统治疗子宫内膜非典型增生的前瞻性随机对照小样本临床研究 |
|
||||
2 | 17:05-17:10 | 论文发言 |
A open-label, multicentre, prospective clinical study evaluating niraparib monotherapy for maintenance of uterine serous carcinoma:Primary outcome update |
|
||||
3 | 17:10-17:15 | 论文发言 |
Immunotherapy and progestin therapy lead to different pathological responses and immune microenvironment as fertility-sparing strategies in MMRd endometrial cancer |
|
||||
4 | 17:15-17:20 | 论文发言 |
Ovarian involvement in fertility-sparing treatment of endometrial cancer |
|
||||
5 | 17:20-17:25 | 论文发言 |
Cell block whole slide image analysis for early endometrial cancer diagnosis in post-menopausal women |
|
||||
6 | 17:25-17:30 | 论文发言 |
IGFBP2 promotes proliferation and glycolysis of endometrial cancer by regulating PKM2/HIF-1α axis |
|
||||
7 | 17:30-17:35 | 论文发言 |
Integrating Homologous Recombination Deficiency Subtyping with TCGA Molecular Classification for Enhanced Prognostic Stratification and Personalized Therapy in Endometrial Cancer |
|
||||
8 | 17:35-17:40 | 论文发言 |
The epidemiological landscape of endometrial cancer worldwide: an analysis of current global patterns, temporal trends, and future burden |
|
||||
9 | 17:40-17:45 | 论文发言 |
MAL2 通过调节氨酰基-tRNA 生物合成促进子宫内膜癌发展 |
|
||||
10 | 17:45-17:50 | 论文发言 |
Correlation of estimated glucose disposal rate with endometrial cancer:cross‑sectional data from the National Health and Nutrition Examination Surveys (NHANES) 1999–2018 |
|
||||
11 | 17:50-18:00 |
讨论交流 |
1 | 08:45-08:52 | 引导报告 |
卵巢癌广泛性腹膜切除术 |
|
||||
2 | 08:52-08:59 | 引导报告 |
卵巢癌“超根治术” |
|
||||
3 | 08:59-09:06 | 引导报告 |
卵巢癌膈肌与肝包膜受侵的手术切除 |
|
||||
4 | 09:06-09:13 | 引导报告 |
卵巢癌肝门腹腔干转移淋巴结切除 |
|
||||
5 | 09:13-09:20 | 引导报告 |
卵巢癌腹腔镜下肿瘤细胞减灭术 |
|
||||
6 | 09:20-09:27 | 引导报告 |
卵巢恶性生殖细胞肿瘤的手术问题 |
|
||||
7 | 09:27-10:30 |
讨论 |
1 | 10:30-11:00 | 专题会发言 |
PARP抑制剂是卵巢癌维持治疗的基石 |
|
1 | 11:00-11:05 | 论文发言 |
Development of a blood cell analysis-based artificial intelligence model for early detection of ovarian cancer |
|
||||
2 | 11:05-11:10 | 论文发言 |
SDC4-MMP14 regulates tumor cell-fibroblast crosstalk and drives epithelial ovarian cancer metastasis through extracellular matrix remodeling |
|
||||
3 | 11:10-11:15 | 论文发言 |
BRCA1/2基因胚系突变卵巢癌患者临床与家系特征分析及高危人群预防现况 |
|
||||
4 | 11:15-11:20 | 论文发言 |
Molecular Subtyping and Its Association with Prognosis in Ovarian Endometrioid Adenocarcinoma |
|
||||
5 | 11:20-11:25 | 论文发言 |
卵巢未成熟畸胎瘤基因组学研究新进展 |
|
||||
6 | 11:25-11:30 | 论文发言 |
信迪利单抗联合紫杉醇周疗和安罗替尼治疗铂耐药复发性上皮性卵巢癌/输卵管癌/原发腹膜腺癌的有效性和安全性的开放、多中心、单臂、II期临床研究的中期分析 |
|
||||
7 | 11:30-11:35 | 论文发言 |
经胸腔镜辅助对比经腹-膈肌入路行卵巢癌心膈角淋巴结切除术的临床分析 |
|
||||
8 | 11:35-11:40 | 论文发言 |
Fertility-sparing Treatment in Early-Stage Endometrial Cancer with Synchronous or Metachronous Ovarian Cancer: Outcomes and Risk Factors |
|
||||
9 | 11:40-11:45 | 论文发言 |
Lactate: An Accomplice in Ovarian Cancer Drug Resistance |
|
||||
10 | 11:45-11:50 | 论文发言 |
Identification of serum peptide biomarker for predicting first-line chemotherapeutic efficacy in advanced ovarian cancer by Clin-TOF-II-MS with magnetic beads technology |
|
||||
11 | 11:50-12:00 |
讨论交流 |
1 | 13:00-13:30 | 专题会发言 |
贝伐珠单抗在卵巢癌中规范化应用及免疫联合治疗探索研究进展 |
|
1 | 13:30-13:38 | 引导报告 |
卵巢癌分子生物学研究进展 |
|
||||
2 | 13:38-13:46 | 引导报告 |
卵巢癌抗血管生成治疗 |
|
||||
3 | 13:46-13:54 | 引导报告 |
卵巢癌PARP抑制剂治疗 |
|
||||
4 | 13:54-14:02 | 引导报告 |
卵巢癌ADC药物治疗 |
|
||||
5 | 14:02-14:10 | 引导报告 |
卵巢癌免疫检查点抑制剂治疗 |
|
||||
6 | 14:10-14:18 | 引导报告 |
卵巢癌其他靶点研究进展 |
|
||||
7 | 14:18-15:30 |
讨论 |
1 | 15:30-16:00 | 专题会发言 |
破解卵巢癌困境:一线维持治疗的策略选择 |
|
1 | 16:00-16:07 | 引导报告 |
卵巢癌质控体系的建设 |
|
||||||||||||||
2 | 16:07-16:14 | 引导报告 |
质控信息化平台的建设 |
|
||||||||||||||
3 | 16:14-16:21 | 引导报告 |
卵巢癌手术的质控管理 |
|
||||||||||||||
4 | 16:21-17:00 |
讨论 |
|
1 | 17:00-17:05 | 论文发言 |
内质网应激反应与卵巢癌铂耐药表型维持的相关性研究 |
|
||||
2 | 17:05-17:10 | 论文发言 |
Long-term Prognosis, Socioeconomic Burdern Analysis Over Time of Children, Adolescents and Young Adults Malignant Ovarian Germ Cell Tumor Survivors |
|
||||
3 | 17:10-17:15 | 论文发言 |
基于血浆游离DNA甲基化标志物的卵巢癌无创早期检测 |
|
||||
4 | 17:15-17:20 | 论文发言 |
卵巢交界性肿瘤保留生育功能治疗的肿瘤结局分析 |
|
||||
5 | 17:20-17:25 | 论文发言 |
尼拉帕利联合安罗替尼用于尼拉帕利维持治疗中CA125升高的卵巢癌:一项开放、单臂、II期临床试验 |
|
||||
6 | 17:25-17:30 | 论文发言 |
Prognostic Modeling of Endometriosis-Associated Ovarian Cancer Based on Molecular Signatures: a Retrospective Study |
|
||||
7 | 17:30-17:35 | 论文发言 |
HSPE1 promotes the occurrence and development of ovarian cancer through stress granules formation |
|
||||
8 | 17:35-17:40 | 论文发言 |
Evaluation the Clinical Response Reputation of Platinum- Based Chemotherapy in Patient-derived Organoids of Ovarian Cancer |
|
||||
9 | 17:40-17:45 | 论文发言 |
BRCA基因突变类型与卵巢上皮癌的临床病理特征 和预后的相关性分析 |
|
||||
10 | 17:45-17:50 | 论文发言 |
以E-选择素为靶点的自组装聚合物胶束对卵巢癌细胞生长的靶向抑制作用 |
|
||||
11 | 17:50-18:00 |
讨论交流 |
1 | 08:00-08:20 | 讲题 |
子宫内膜癌卵巢受累 |
|
||||||||||||||||
2 | 08:20-09:00 |
病例讨论1 |
|
|||||||||||||||||
3 | 09:00-09:20 | 讲题 |
子宫颈癌卵巢受累 |
|
||||||||||||||||
4 | 09:20-10:00 |
病例讨论2 |
|
1 | 10:00-10:30 | 专题会发言 |
宫颈癌免疫治疗进展 |
|
1 | 10:30-10:37 | 引导报告 |
妇科肿瘤基因检测和遗传咨询指南要点 |
|
||||||||||||||
2 | 10:37-10:44 | 引导报告 |
预防性切除与遗传干预 |
|
||||||||||||||
3 | 10:44-10:51 | 引导报告 |
遗传性肿瘤的分子检测要点 |
|
||||||||||||||
4 | 10:51-11:30 |
讨论 |
|
1 | 11:30-11:35 | 论文发言 |
肿瘤细胞AIG1通过降低CD8+T细胞浸润和杀伤影响预后 |
|
||||
2 | 11:35-11:40 | 论文发言 |
郭氏缝合法与改良Sturmdorf缝合法在子宫颈冷刀锥切术中应用效果的对比分析 |
|
||||
3 | 11:40-11:45 | 论文发言 |
基于多组学的双硫死亡调节子泛癌图谱研究 |
|
||||
4 | 11:45-11:50 | 论文发言 |
辅助生殖技术在交界性肿瘤术后患者应用的有效性及安全性——一项回顾性队列研究 |
|
||||
5 | 11:50-11:55 | 论文发言 |
Establishment and Chemotherapeutic Drug Testing of Patient-Derived Organoids from Gestational Trophoblastic Neoplasia |
|
||||
6 | 11:55-12:00 |
讨论交流 |
1 | 08:00-08:08 | 引导报告 |
GTN预后评分的临床应用与争议 |
|
||||||||||||||||||||||
2 | 08:08-08:16 | 引导报告 |
绒癌组织学起源的分类及对临床诊疗的指导意义 |
|
||||||||||||||||||||||
3 | 08:16-08:24 | 引导报告 |
低危滋养细胞肿瘤治疗方案的选择 |
|
||||||||||||||||||||||
4 | 08:24-08:32 | 引导报告 |
高危滋养细胞肿瘤治疗方案的选择 |
|
||||||||||||||||||||||
5 | 08:32-08:40 | 引导报告 |
PSTT的研究现状与进展 |
|
||||||||||||||||||||||
6 | 08:40-08:48 | 引导报告 |
ETT的研究现状与进展 |
|
||||||||||||||||||||||
7 | 08:48-10:00 |
讨论 |
|
1 | 10:00-10:30 | 专题会发言 |
复发转移性宫颈癌系统治疗的演进与循证 |
|
1 | 10:30-10:37 | 引导报告 |
新免疫时代下的放疗变革 |
|
||||||||||||||
2 | 10:37-10:44 | 引导报告 |
子宫颈癌术后辅助治疗的选择 |
|
||||||||||||||
3 | 10:44-10:51 | 引导报告 |
子宫颈癌放射治疗技术进展 |
|
||||||||||||||
4 | 10:51-11:30 |
讨论 |
|
1 | 11:30-11:35 | 论文发言 |
Optimizing Chemo-Immunotherapy for Cervical Cancer by Harnessing Time-Dependent Immune Modulation in the Tumor Microenvironment |
|
||||
2 | 11:35-11:40 | 论文发言 |
Integrated Spatial Multi-omics Delineates Fatty Acid Degradation Fuels Malignant Evolution at the Tumor Periphery in Cervical Squamous Cell Carcinoma |
|
||||
3 | 11:40-11:45 | 论文发言 |
Timing, Surgical Approach, and Uterine Manipulator Use in Total Hysterectomy After loop electrosurgical excision procedure (LEEP): Implications for Perioperative Risks in high-grade squamous intraepithelial lesion (HSIL) Patients |
|
||||
4 | 11:45-11:50 | 论文发言 |
Development and validation of prediction model for adnexal metastases in early-stage cervical adenocarcinoma: A multicenter study |
|
||||
5 | 11:50-11:55 | 论文发言 |
Correlation Study and Prognostic Analysis of Tumor-Free Distance (TFD) Measured by MRI Before Cervical Cancer Treatment and Postoperative Pathological Factors |
|
||||
6 | 11:55-12:00 |
讨论交流 |
1 | 08:00-08:07 | 引导报告 |
子宫内膜癌筛查首都模式 |
|
||||||||||||||
2 | 08:07-08:14 | 引导报告 |
子宫内膜癌筛查方法 |
|
||||||||||||||
3 | 08:14-08:21 | 引导报告 |
中国子宫内膜癌筛查多中心研究结果汇报 |
|
||||||||||||||
4 | 08:21-09:00 |
讨论 |
|
|||||||||||||||
5 | 09:00-09:07 | 引导报告 |
子宫内膜癌患者保育的挑战与对策 |
|
||||||||||||||
6 | 09:07-09:14 | 引导报告 |
子宫内膜癌的分子特征与腹腔镜手术安全性初步探索 |
|
||||||||||||||
7 | 09:14-09:21 | 引导报告 |
子宫内膜癌保育“一抗三降”新方案 |
|
||||||||||||||
8 | 09:21-10:00 |
讨论 |
|
1 | 10:00-10:30 | 专题会发言 |
妇科恶性肿瘤支持治疗临床实践与规范化全程管理策略 |
|
1 | 10:30-10:37 | 引导报告 |
子宫内膜癌术后辅助治疗 |
|
||||||||||||||
2 | 10:37-10:44 | 引导报告 |
晚期转移/复发子宫内膜癌一线治疗 |
|
||||||||||||||
3 | 10:44-10:51 | 引导报告 |
晚期转移/复发子宫内膜癌后线治疗 |
|
||||||||||||||
4 | 10:51-11:30 |
讨论 |
|
1 | 11:30-11:35 | 论文发言 |
Aneuploidy information and Its Association with Gene Expression Profiles and Recurrence Risks in Endometrial Carcinoma |
|
||||
2 | 11:35-11:40 | 论文发言 |
Development and validation of a novel prognostic scoring system for early-stage endometrial cancer: a Chinese multicenter study |
|
||||
3 | 11:40-11:45 | 论文发言 |
瑞舒伐他汀联合醋酸甲地孕酮治疗子宫内膜非典型增生单中心开放性临床研究 |
|
||||
4 | 11:45-11:50 | 论文发言 |
淋巴脉管癌栓对病理淋巴结阴性早期子宫内膜癌预后及辅助治疗选择的影响 |
|
||||
5 | 11:50-11:55 | 论文发言 |
Development of a Predictive Model Integrating Pathological and Clinical Factors for Fertility-Sparing Treatment in Patients with Atypical Endometrial Hyperplasia and Endometrial Carcinoma |
|
||||
6 | 11:55-12:00 |
讨论交流 |
1 | 08:00-08:40 | 辩题 |
复发性卵巢癌患者生存时长重要还是生活质量重要 |
|
||||||||||||||||||
2 | 08:40-09:20 | 辩题 |
子宫内膜癌诊断首选宫腔镜还是诊断性刮宫 |
|
||||||||||||||||||
3 | 09:20-10:00 | 辩题 |
晚期卵巢癌新辅助化疗是与非 |
|
1 | 10:00-10:30 | 专题会发言 |
晚期卵巢癌的全程规范化管理 |
|
1 | 10:30-10:37 | 引导报告 |
子宫平滑肌肉瘤病理分子特征 |
|
||||||||||||||
2 | 10:37-10:44 | 引导报告 |
子宫平滑肌肉瘤的治疗 |
|
||||||||||||||
3 | 10:44-10:51 | 引导报告 |
子宫内膜间质肉瘤的治疗 |
|
||||||||||||||
4 | 10:51-11:30 |
讨论 |
|
1 | 11:30-11:35 | 论文发言 |
Does Delayed Surgery Affect Survival in Recurrent Ovarian Adult-Type Granulosa Cell Tumor? A Retrospective Study from a High-Volume Medical Center |
|
||||
2 | 11:35-11:40 | 论文发言 |
RPA70 和 ATR 抑制剂通过诱导治疗性BRCAness增强奥拉帕利在BRCA1/2野生型卵巢癌中的抗肿瘤效应 |
|
||||
3 | 11:40-11:45 | 论文发言 |
上皮性卵巢癌血浆差异基因miRNA-3187-3p靶向PLK2调节细胞增殖与凋亡的机制研究 |
|
||||
4 | 11:45-11:50 | 论文发言 |
Survival of surgery for platinum-sensitive relapsed ovarian cancer: a systematic review and meta-analysis of individual participant data from randomised trials |
|
||||
5 | 11:50-11:55 | 论文发言 |
Mesothelin-targeted CAR-T Therapy FC004 for Platinum-resistant Ovarian Cancer: A Phase I Trial |
|
||||
6 | 11:55-12:00 |
讨论交流 |